scispace - formally typeset
J

Jun Ma

Researcher at Harbin Institute of Technology

Publications -  1523
Citations -  58397

Jun Ma is an academic researcher from Harbin Institute of Technology. The author has contributed to research in topics: Nasopharyngeal carcinoma & Medicine. The author has an hindex of 97, co-authored 1338 publications receiving 39643 citations. Previous affiliations of Jun Ma include Shenyang Aerospace University & University of Technology, Sydney.

Papers
More filters
Journal ArticleDOI

Melt compounding with graphene to develop functional, high-performance elastomers

TL;DR: This simple fabrication of 3.56 nm thick graphene platelets of high structural integrity to melt compound with an elastomer-ethylene-propylene-diene monomer rubber (EPDM) would prolong the service life of elastomers used in dynamic loading, thus reducing thermosetting waste in the environment.
Journal ArticleDOI

Preparation and characterization of PAA/PVDF membrane-immobilized Pd/Fe nanoparticles for dechlorination of trichloroacetic acid.

TL;DR: The stability of Pd/Fe NP membrane system was tested, and the kinetics and product distribution of dechlorination of trichloroacetic acid by Pd-Fe NP membranes system were discussed.
Journal ArticleDOI

Comparison of diamino cross-linking in different polyimide solutions and membranes by precipitation observation and gas transport

TL;DR: In this article, diamino cross-linking processes in solution and dense membrane forms were investigated and the cross-linked network in Matrimid/dichloromethane (CH2Cl2) solutions appeared much faster than that in 6FDA-durene/CH2CL2 solutions.
Journal ArticleDOI

Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China.

TL;DR: The objective of this study was to evaluate the long‐term survival and late toxicities of concurrent‐adjuvant chemotherapy in patients with stage III through IVB nasopharyngeal carcinoma from endemic regions of China.